AI assistant
NovoCure Ltd — Director's Dealing 2025
Mar 3, 2025
31949_dirs_2025-03-03_60a6397a-78ce-45bd-8491-8321e93bf2bb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2025-02-27
Reporting Person: Leupin Nicolas (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-27 | Ordinary Shares | S | 830.00 | $19.9219 | Disposed | 50294.00 | Direct |
| 2025-02-27 | Ordinary Shares | S | 161.00 | $20.549 | Disposed | 50133.00 | Direct |
Footnotes
F1: On February 27, 2025, the reporting person sold 830 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F2: On February 27, 2025, the reporting person sold 161 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.